SpringerLink
Log in

Effects of octreotide on biliary lipid composition and occurrence of cholesterol crystals in patients with acromegaly

A prospective study

  • Pancreatic And Biliary Disordens
  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

Abstract

Treatment with the somatostatin analog octreotide is associated with increased gallstone formation. The mechanism of formation of these stones is unclear. The purpose of this study was to examine the effect of a three-month treatment with octreotide on biliary lipid composition and the occurrence of cholesterol crystals in patients with acromegaly. Thirteen patients with active acromegaly, aged 24–76 years, received octreotide (100 µg three times daily) for three months. Fasting gallbladder bile was obtained during upper gastrointestinal endoscopy after ceruletide stimulation. Bile was studied before and at the end of the treatment period (N=7), only before (N=4), or only at the end of treatment (N=2). Before treatment, all bile samples but one were supersaturated with cholesterol. However, none contained cholesterol crystals on microscopic examination. At the end of the treatment period, all but two samples were supersaturated with cholesterol. Three of nine samples contained cholesterol crystals, a proportion significantly higher than before treatment. The relative proportions of bile acids, cholesterol, and phospholipids, and the mean cholesterol saturation index were not different before and during treatment. Follow-up ultrasonography showed the occurrence of gallstones in four patients, including the three patients who had cholesterol crystals. We conclude that: (1) fasting gallbladder bile of patients with acromegaly is frequently supersaturated with cholesterol; (2) treatment with octreotide does not increase cholesterol saturation index, but may induce the occurrence of cholesterol crystals. The data are consistent with the view that gallstones induced by octreotide are cholesterol stones and suggest that the drug may impair gallbladder motility and/or decrease cholesterol nucleation time.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Comi RJ, Maton PN, Go VLW: Somatostatin and somatostatin analogue (octreotide) in treatment of hormone-secreting tumors of the pituitary and gastro-intestinal tract and non-neoplasic diseases of the gut. Ann Intern Med 110:35–50, 1989

    Google Scholar 

  2. Ho KY, Weissberger AJ, Marbach P, Lazaras L: Therapeutic efficacy of the somatostatin analog SMS 201-995 (octreotide) in acromegaly: Effect of dose and frequency and long-term safety. Ann Intern Med 112:173–181, 1990

    Google Scholar 

  3. Hopman WPM, van Liessum PA, Pieters GFFM, et al: Pancreatic exocrine and gallbladder function during long-term treatment with octreotide (SMS 201-995). Digestion 45(suppl 1):72–76, 1990

    Google Scholar 

  4. Buscail L, Tauber JP, Escourrou J, et al: Gallstone formation and occurrence of cholesterol monohydrate crystals in gallbladder bile of patients with long-term Sandostatin treatment. Gastroenterol Clin Biol 15:800–804, 1991

    Google Scholar 

  5. Wass JAH, Anderson JV, Besser GM: Gallstones and treatment with octreotide for acromegaly. Br Med J 299:1162–1163, 1989 (letter)

    Google Scholar 

  6. McKnight JA, McCance DR, Crothers JG, Atkinson AB: Changes in glucose tolerance and development of gall stones during high dose treatment with octreotide for acromegaly. Br Med J 299:604–605, 1989

    Google Scholar 

  7. Boden G, Shimoyana R: Somatostatinoma.In Hormone-Producing Tumors of the Gastrointestinal Tract. S Cohen, RD Soloway (eds). New York, Churchill Livingstone, 1985, pp 85–99

    Google Scholar 

  8. Christensen SE: Somatostatinoma.In Recent Advances in Diabetes. M Nattrass (ed). New York, Churchill Livingstone, 1986, pp 61–70

    Google Scholar 

  9. Fisher RS, Rock E, Levin G, Malmud L: Effects of somatostatin on gallbladder emptying. Gastroenterology 92:885–890, 1987

    Google Scholar 

  10. Creutzfeldt W, Lankisch PG, Fölsch UR: Hemmung der Sekretin- und Cholecystokinin-Pankreozymin-induzierten Salft- und Enzymsekretion des Pankreas und der Gallenblasenkontraktion beim Menschen durch Somatostatin. Dtsch Med Wochenschr 100:1135–1138, 1975

    Google Scholar 

  11. Lankisch PG, Arnold R, Creutzfeldt W: Wirkung von Somatostatin auf die Betazol-stimulierte Magensekretion und die Carbachol-stimulierte Pankreassekretion und die Gallenblasenkontraktion des Menschen. Dtsch Med Wochenschr 100:1797–1800, 1975

    Google Scholar 

  12. Johansson C, Kollberg B, Efendic S, Uvnäs-Wallensten K: Effect of graded doses of somatostatin on gallbladder emptying and pancreatic enzyme output after oral glucose in man. Digestion 22:24–31, 1981

    Google Scholar 

  13. Lembcke B, Creutzfeldt W, Schleser R, Ebert C, Shaw C, Koop I: Effect of the somatostatin analogue sandostatin (octreotide) on gastrointestinal, pancreatic and biliary function and hormone release in normal men. Digestion 36:108–124, 1987

    Google Scholar 

  14. Sedaghat A, Grundy SM: Cholesterol crystals and the formation of cholesterol gallstones. N Engl J Med 302:1274–1277, 1980

    Google Scholar 

  15. Berthelot P, Erlinger S, Dhumeaux D, Preaux AM: Mechanism of phenobarbital-induced hypercholeresis in the rat. Am J Physiol 219:809–813, 1970

    Google Scholar 

  16. Aufenanger J, Kattermann R: Enzymatic determination of lipids in human bile without bilirubin interference: Reliable assessment of the cholesterol saturation index (CSI). J Clin Chem Clin Biochem 27:605–611, 1989

    Google Scholar 

  17. Carey MC: Critical tables for calculating the cholesterol saturation of native bile. J Lipid Res 19:945–955, 1978

    Google Scholar 

  18. Timsit J, Chanson P, Larger E, et al: The effect of subcutaneous infusion versus subcutaneous injections of somatostatin analogue (octreotide) on the diurnal profile of GH in acromegaly. Acta Endocrinol (Copenhagen) 116:108–112, 1987

    Google Scholar 

  19. Chanson P, Timsit J, Masquet C, et al: Cardiovascular effects of the somatostatin analogue octreotide in acromegaly. Ann Intern Med 113:921–925, 1990

    Google Scholar 

  20. Holzbach RT, Marsh M, Olszewski M, Holan K: Cholesterol solubility in bile. Evidence that supersaturated bile is frequent in healthy man. J Clin Invest 52:1467–1479, 1973

    Google Scholar 

  21. Catnach SM, Anderson JV, Parker E, Wass JAH, Besser GM, Fairclough PD: Gallbladder emptying and gallstone formation in acromegalics treated with octreotide. Gastroenterology 100:A312, 1991

    Google Scholar 

  22. Van Erpecum KJ, Van Berge Henegouwen GP: Pathogenetic factors in cholesterol gallstones disease. Scan J Gastroenterol 24(suppl 171):83–90, 1989

    Google Scholar 

  23. Zhu XF, Shi YF, Quin-Dai, Zhang JX, Harris AG: Effect of small doses of somatostatin analogue, octreotide, on gallbladder contractility in normal chinese adults. Dig Dis Sci 37:105–108, 1992

    Google Scholar 

  24. Van Liessum PA, Hopman WPM, Pieters GFFM, et al: Postprandial gallbladder motility during long term treatment with the long-acting somatostatin analog SMS 201-995 in acromegaly. J Clin Endocr Metab 69:557–562, 1989

    Google Scholar 

  25. Souquet JC, Girard I, Sassolas G, et al: Etude de la vidange vésiculaire chez l'acromégale traité par Sandostatine®. Gastroenterol Clin Biol 15:A103, 1991 (abstract).

    Google Scholar 

  26. Ahrendt SA, McGuire GE, Pitt HA, Lillemoe KD: Why does somatostatin cause gallstones? Am J Surg 161:177–182, 1991

    Google Scholar 

  27. Hussaini SH, Murphy GM, Kennedy C, Wass JAH, Dowling RH: Octreotide associated gallbladder stone (GBS) characteristics and gallbladder bile chemistry. Proceedings of the Sandostatin® 1991 State of the Art Symposium, Monte Carlo. October 1991

Download references

Author information

Authors and Affiliations

  1. From the Service d'Hépatologie and INSERM U-24, Hôpital Beaujon, Clichy

    S. Erlinger, P. Chanson, M. Dumont, P. Ponsot, A. Warnet & A. G. Harris

  2. Service de Médecine Interne, Nutrition, Endocrinologie, Hôpital Lariboisière, Paris

    S. Erlinger, P. Chanson, M. Dumont, P. Ponsot, A. Warnet & A. G. Harris

  3. Service de Gastroentérologie, Hôpital Beaujon, Clichy, France

    S. Erlinger, P. Chanson, M. Dumont, P. Ponsot, A. Warnet & A. G. Harris

  4. Division of Clinical Pharmacology, Department of Medicine, Cedars Sinai Medical Center, Los Angeles, California

    S. Erlinger, P. Chanson, M. Dumont, P. Ponsot, A. Warnet & A. G. Harris

Authors
  1. S. Erlinger
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P. Chanson
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. Dumont
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. P. Ponsot
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. A. Warnet
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. A. G. Harris
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Erlinger, S., Chanson, P., Dumont, M. et al. Effects of octreotide on biliary lipid composition and occurrence of cholesterol crystals in patients with acromegaly. Digest Dis Sci 39, 2384–2388 (1994). https://doi.org/10.1007/BF02087655

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02087655

Key words

Search

Navigation